Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexrazoxane for Doxorubicin-induced cardiotoxicity prevention
NCT03930680Phase 1Completed
- Sponsor
- University of Arkansas
- Start
- Sep 2021
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of dexrazoxane in Cardiotoxicity (5 arms), sponsored by University of Arkansas. Primary endpoint: Participants With 95% Reduction in Topoisomerase 2 b From Baseline at 8 hours. Started Sep 2021; status: completed.
02
Drugs
dexrazoxane
03
Conditions
Cardiotoxicity
Beyond the preview
Go deeper on NCT03930680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03930680.